Cargando…

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Xiang, Minqi, Qian, Xu, Han, Luyu, Wang, Hui, Wang, Jiqiu, Liu, Weiren, Gu, Yanyun, Yao, Shuangshuang, Yang, Jian, Zhang, Yifei, Peng, Ying, Zhang, Zhiguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485148/ https://www.ncbi.nlm.nih.gov/pubmed/37694153 http://dx.doi.org/10.1016/j.isci.2023.107724

Ejemplares similares

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress
por: Zhang, Zhiguo, et al.
Publicado: (2016)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
por: Prawitt, Janne, et al.
Publicado: (2011)

Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
por: Gonzalez, Frank J., et al.
Publicado: (2015)

PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation
por: Tong, Lei, et al.
Publicado: (2019)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
por: Zhu, Yanlin, et al.
Publicado: (2020)

Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling
por: Paraiso, Ines L., et al.
Publicado: (2021)

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
por: Jiang, Changtao, et al.
Publicado: (2015)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation
por: Li, Hongshan, et al.
Publicado: (2022)

Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice
por: Jiang, Jie, et al.
Publicado: (2022)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
por: Liu, Xijun, et al.
Publicado: (2015)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
por: Wang, Hong, et al.
Publicado: (2018)

Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis
por: LIAN, FAN, et al.
Publicado: (2015)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

Investigating the Role of Farnesoid X Receptor in Heme Biosynthesis and Ductular Reaction
por: Dean, Angela E, et al.
Publicado: (2021)

Stimulation of the farnesoid X receptor promotes M2 macrophage polarization
por: Jaroonwitchawan, Thiranut, et al.
Publicado: (2023)

Enhanced Alcoholic Liver Disease in Mice with Intestine-specific Farnesoid X Receptor Deficiency
por: Huang, Mingxing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nr92qs1etnae4jpagivd416inr